US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Super League Gaming Inc.

0.2350

-0.0310-11.65%

Volume:250.45K

Turnover:59.46K

Market Cap:3.90M

PE:-0.05

High:0.2611

Open:0.2580

Low:0.2200

Close:0.2660

Loading ...

Overview Company News Filings

Super League Enterprise, Inc. : H.c. Wainwright Cuts Target Price to $2 From $3

THOMSON REUTERS

FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Super League Enterprise Inc reports results for the quarter ended September 30 - Earnings Summary

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Teen in SLE bike chase that killed LTA officer gets guilty plea pushed to January

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Super League Enterprise Q3 2024 Adj EPS $(0.25) Beats $(0.31) Estimate, Sales $4.43M Miss $6.81M Estimate

Super League Announces Third Quarter 2024 Financial Results

THOMSON REUTERS

Press Release: Super League Announces Third Quarter 2024 Financial Results

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/SLE/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":0.235,"timestamp":1743451200000,"preClose":0.266,"halted":0,"volume":250453,"delay":0,"floatShares":11261099,"shares":16604922,"eps":-4.481745,"marketStatus":"Post-Market Trading","change":-0.031,"latestTime":"03-31 16:02:37 EDT","open":0.258,"high":0.2611,"low":0.22,"amount":59460.51015,"amplitude":0.154511,"askPrice":0.26,"askSize":5000,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.481745,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743465600000},"marketStatusCode":4,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":0.266,"preHourTrading":{"tag":"盘前","latestPrice":0.2659,"preClose":0.266,"latestTime":"09:18 EDT","volume":329,"amount":86.37099807,"timestamp":1743427112285},"volumeRatio":0.985036},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":11261099,"roa":"-54.85%","roe":"-244.57%","lyrEps":-13.672882,"volumeRatio":0.985036,"shares":16604922,"dividePrice":0,"high":0.2611,"amplitude":0.154511,"preClose":0.266,"low":0.22,"week52Low":0.22,"pbRate":"1.11","psRate":"0.18","week52High":2.38,"institutionHeld":0,"latestPrice":0.235,"committee":-1,"eps":-4.481745,"divideRate":0,"volume":250453,"delay":0,"ttmEps":-4.481745,"open":0.258,"prevYearClose":0.6175,"prevWeekClose":0.266,"prevMonthClose":0.381,"prevQuarterClose":0.6175,"fiveDayClose":0.361,"twentyDayClose":0.334,"sixtyDayClose":0.6175},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:16,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2484196503","title":"Super League Enterprise, Inc. : H.c. Wainwright Cuts Target Price to $2 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2484196503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484196503?lang=en_us&edition=fundamental","pubTime":"2024-11-20 19:01","pubTimestamp":1732100511,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nAZN2NDTWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2484903430","title":"FATE Presents Encourgaing Data From Lupus Study, Stock Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903430","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484903430?lang=en_us&edition=fundamental","pubTime":"2024-11-20 02:55","pubTimestamp":1732042500,"startTime":"0","endTime":"0","summary":"Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate FT819.Data showed that the first patient suffering from active lupus nephritis  and treated with FT819 had favorable clinical experience, achieved drug-free clinical remission and continued on-study free of all immunosuppressive therapy.Shares of Fate have lost 42.8% year to date compared with the industry’s decline of 11.1%.FT819 is FATE’s off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.The initial results are promising, and FATE believes this differentiated therapeutic approach has the potential to transform outcomes for patients with autoimmune diseases without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy and extended hospital","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/j1FS0yeEY913fehDKxmAwA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/j1FS0yeEY913fehDKxmAwA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-presents-encourgaing-data-lupus-185500828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","FATE","BK4196","SLE","CSTL","SPRO","BK4077","BK4505","IMCR"],"gpt_icon":0},{"id":"2484562620","title":"Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2484562620","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484562620?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:30","pubTimestamp":1731936600,"startTime":"0","endTime":"0","summary":"ALLO-329 Induces Deep, Transient Depletion of CD19+ B Cells and CD70+ T Cells, and Reduction in IgG and IgM without Lymphodepletion in Humanized Murine ModelsProprietary Dagger Technology Enables ALLO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/18/2982777/0/en/Allogene-Therapeutics-Presents-Preclinical-Data-for-ALLO-329-an-Allogeneic-CD19-CD70-Dual-CAR-T-for-the-Treatment-of-Autoimmune-Disease-at-the-American-College-of-Rheumatology-ACR-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4139","MLR","SLE","CAR","BK4149","BK4117","BK4505","BK4077","ACR","BK4110","BK4230","BK4022","BK4107","ALLO","TRAC","AFG"],"gpt_icon":0},{"id":"2484622908","title":"Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2484622908","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484622908?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:05","pubTimestamp":1731935100,"startTime":"0","endTime":"0","summary":"27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Pat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/18/2982757/24675/en/Fate-Therapeutics-Presents-6-Month-Follow-up-Data-on-First-Patient-Treated-in-Phase-1-Autoimmunity-Study-with-Fludarabine-free-Conditioning-and-FT819-Off-the-shelf-1XX-CAR-T-cell-P.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","ASH","IE00B19Z4B17.USD","SLE","CAR","IE0031619046.USD","IE00B7SZL793.SGD","ACR","BK4109","BK4110","BK4006","BK4139","FATE","IE00B66KJ199.SGD","BK4077","BK4230","CRS","BK4022"],"gpt_icon":1},{"id":"2484521622","title":"Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2484521622","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484521622?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:00","pubTimestamp":1731934800,"startTime":"0","endTime":"0","summary":"Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens without Conditioning Chemotherapy Initial Phase 1 Clinical","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/18/2982736/24675/en/Fate-Therapeutics-Highlights-FT522-Off-the-shelf-ADR-armed-CAR-NK-Cell-Product-Candidate-at-2024-ACR-Convergence.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SD","FATE","BK4139","BK4006","PK","CR","ACR","IE0031619046.USD","BK4161","BK4213","BK4077","BK4230","BK4110","SLE","CRS","BK4022","PR","BK4218","IE00B19Z4B17.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","CAR","BK4181"],"gpt_icon":1},{"id":"2484629123","title":"Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2484629123","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484629123?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931200,"startTime":"0","endTime":"0","summary":"Preliminary clinical data in LN anticipated in 1H25. Initiation of patient enrollment in systemic lupus erythematosus , systemic sclerosis , idiopathic inflammatory myopathy  and stiff person syndrome  expected in 1Q25; patient enrollment in anti-neutrophil cytoplasmic autoantibody  associated vasculitis  expected in 2H25. The Phase 1 study has four separate arms, enrolling LN and SLE patients into one arm, SSc patients into a second arm, IIM and SPS patients in a third arm and AAV patients into a fourth arm. Enrolled patients will receive a single dose of ADI-001. The dose-limiting toxicity window is 28 days with response and safety assessments conducted on Day 28 and during the follow up period on months 3, 6, 9, 12, 18 and 24. The primary objectives of the study are to evaluate the safety and tolerability of ADI-001. Secondary objectives include measuring cellular kinetics, pharmacod","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XpX5aBn6VdM8LbAAE_bE3g--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a863b0d98611ba55695cfeb883a2aff1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XpX5aBn6VdM8LbAAE_bE3g--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a863b0d98611ba55695cfeb883a2aff1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-announces-first-lupus-120000573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443622.USD","BK4512","LU2237443978.SGD","ADI","LU1815336760.USD","LU0314104364.USD","LU2272731782.SGD","LU0082616367.USD","IE0009356076.USD","BK4515","IE00B5949003.HKD","LU0109392836.USD","LU0724618433.USD","LU1642822529.SGD","LU1244550577.SGD","LU2237443382.USD","IIM","LU1670710661.SGD","LU2360107325.USD","IE00BZ199S13.USD","BK4139","LU0889565833.HKD","LU1670711040.USD","LU1861219969.SGD","LU2298322129.HKD","LU1244550221.USD","LU0957808578.USD","LU0444971666.USD","LU1992135472.HKD","LU2272731600.USD","BK4588","LU2458330243.SGD","LU2237443549.SGD","LU1670710588.SGD","BK4585","BK4561","LU1074936037.SGD","BK4077","LU0124384867.USD","LU1803068979.SGD","LU1244550494.USD","LU1992135399.USD","SLE","LU2237438978.USD","ACET","BK4141","IE00BD6J9T35.USD","LU1978683503.SGD","LU1861214812.USD","LU2458330169.SGD"],"gpt_icon":0},{"id":"2484626188","title":"Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484626188","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484626188?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931200,"startTime":"0","endTime":"0","summary":"– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event –。– All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion and through the follow-up period –。– Consistent and complete B cell depletion observed in all patients within the first month after CABA-201 infusion; evidence of transitional nave B cell repopulation as early as eight weeks in the first two patients –。– 40 U.S. clinical sites actively recruiting across the RESET clinical development program, with 16 patients enrolled and 10 patients dosed with CABA-201 as of November 12, 2024 –","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cabaletta-bio-presents-positive-clinical-120000795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","IMNM","IE00B7SZL793.SGD","CABA","ACR","SLE","IE0031619046.USD","BK4006","BK4161","BK4546","DM","BK4563","IE00B66KJ199.SGD","BK4139","BK4110","CRS","IE00B19Z4B17.USD"],"gpt_icon":1},{"id":"2483514693","title":"Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483514693","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483514693?lang=en_us&edition=fundamental","pubTime":"2024-11-16 22:00","pubTimestamp":1731765600,"startTime":"0","endTime":"0","summary":"-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue. -Results highlight the potential benefits unique to gamma delta 1 CAR T cell therapy and ADI-001's potential as a best-in-class off-the-shelf cell therapy for autoimmune diseases. REDWOOD CITY, Calif. & BOSTON, November 16, 2024----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates robust tissue homing, significant CAR T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue will be featured in an oral session at ACR Convergence 2024 in Washington, D.C., November 14-19.Concurrent with ADI-001 tissue trafficking and activation, complete depl","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Rye59Ues0jMwXKyZll4xfA--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/699cc1b32c1c1113d633cc9434ab438e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Rye59Ues0jMwXKyZll4xfA--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/699cc1b32c1c1113d633cc9434ab438e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-presents-clinical-biomarker-140000237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE","BK4117","ACET","BK4077","ACR","BK4230","AFG","CAR","BK4022","IIM","BK4107","BK4139","BK4110"],"gpt_icon":0},{"id":"2483371482","title":"Super League Enterprise Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483371482","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483371482?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:13","pubTimestamp":1731680011,"startTime":"0","endTime":"0","summary":"* Super League Enterprise Inc    reported a quarterly adjusted loss of 33 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Super League Enterprise Inc reports results for the quarter ended September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE"],"gpt_icon":0},{"id":"2483257393","title":"Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483257393","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483257393?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:00","pubTimestamp":1731668400,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. & EDMONTON, Alberta, November 15, 2024----Aurinia Pharmaceuticals Inc.  , announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence  2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis , a serious manifestation of systemic lupus erythematosus , and reinforce the clinical importance of LUPKYNIS , a second generation calcineurin inhibitor , for the treatment of adults with active LN.An analysis from the Phase 3 AURORA 1 and 2 studies highlighted the long-term efficacy of LUPKYNIS in people with LN. This study focused on a new efficacy endpoint, sustained complete renal response , defined by the United States Food and Drug Administration  as achieving a complete renal response  at 12 months in AURORA 1 and at all study visits in the 2-year AURORA 2 continuation study. Significantly more LUPKYNIS patients achieved SCRR compared to patients ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5E7r.Ca9i8SEtHG1_H3rTQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8491453ee67c4f90fc15c15f7d4e54b6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5E7r.Ca9i8SEtHG1_H3rTQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8491453ee67c4f90fc15c15f7d4e54b6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-presents-data-underscoring-critical-110000086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","CNI","BK4557","BK4117","ACR","AUPH","BK4107","AFG","BK4016","BK4007","SLE","BK4110","ACB","BK4139"],"gpt_icon":1},{"id":"2483396070","title":"Teen in SLE bike chase that killed LTA officer gets guilty plea pushed to January","url":"https://stock-news.laohu8.com/highlight/detail?id=2483396070","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483396070?lang=en_us&edition=fundamental","pubTime":"2024-11-15 11:24","pubTimestamp":1731641086,"startTime":"0","endTime":"0","summary":"The defence sought the adjournment saying a document had been filed only a few days ago and he needed time to go through it with his client.","market":"sg","thumbnail":"https://onecms-res.cloudinary.com/image/upload/s--bpHb1jwL--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2024/09/20/lta%20enforcement%20officer%20accident.jpg?itok=L-kkc82X","type":0,"news_type":0,"thumbnails":["https://onecms-res.cloudinary.com/image/upload/s--bpHb1jwL--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2024/09/20/lta%20enforcement%20officer%20accident.jpg?itok=L-kkc82X"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/teen-sle-bike-chase-lta-officer-killed-guilty-plea-jail-drugs-4749321","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["LU1543694498.USD","LU1596574779.USD","BK4585","LU1620156130.USD","BK4588","SLE","LU1620156213.USD","LU1721427968.SGD","LU2413665964.HKD","LU1165135440.EUR","BK4077","AOS","BK4086","LU2413666004.HKD"],"gpt_icon":0},{"id":"2483358945","title":"Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2483358945","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483358945?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:30","pubTimestamp":1731619800,"startTime":"0","endTime":"0","summary":"Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune diseaseCARLSBAD, Calif., Nov.  14, 2024  (GLOBE NEWSWIRE) -- Exagen Inc., ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981652/32920/en/Exagen-Inc-Completes-Validation-and-Regulatory-Submission-for-New-Lupus-and-Rheumatoid-Arthritis-Biomarkers-on-the-AVISE-CTD-Platform.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XGN","RA","BK4077","BK4139","SLE"],"gpt_icon":0},{"id":"2483302143","title":"Super League Enterprise Q3 2024 Adj EPS $(0.25) Beats $(0.31) Estimate, Sales $4.43M Miss $6.81M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483302143","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483302143?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:23","pubTimestamp":1731619394,"startTime":"0","endTime":"0","summary":"Super League Enterprise (NASDAQ:SLE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.31) by 19.35 percent. This is a 78.45 percent increase over losses of $(1.16) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41990441/super-league-enterprise-q3-2024-adj-eps-0-25-beats-0-31-estimate-sales-4-43m-miss-6-81m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Super League Enterprise Q3 2024 Adj EPS $(0.25) Beats $(0.31) Estimate, Sales $4.43M Miss $6.81M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE"],"gpt_icon":0},{"id":"2483306373","title":"Super League Announces Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483306373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483306373?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:20","pubTimestamp":1731619200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA1YW07B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2483330156","title":"Press Release: Super League Announces Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483330156","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483330156?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:20","pubTimestamp":1731619200,"startTime":"0","endTime":"0","summary":"Third Quarter Highlighted by Transformative Agreement and Anticipated Strategic Investment from Infinite Reality including Merger of World-Class Audience Assets. Q3 Net Loss Per Share Narrows to Improve Operational Efficiency on Continued Reduction in Operating Expenses. SANTA MONICA, Calif., Nov. 14, 2024  -- Super League , a leader in redefining the gaming industry as a media channel, today announced that it has released third quarter 2024 financial results in the form of a shareholder letter, which can be accessed under the Quarterly Results section of the Company's investor relations website.Looking ahead, our product and technology approach are how we scale market adoption by leading global brands as we co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2483258337","title":"Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483258337","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483258337?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Nov.  14, 2024  (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981606/0/en/Alumis-Presents-Data-Highlighting-ESK-001-s-Potential-as-a-High-efficacy-Oral-Treatment-for-Systemic-Lupus-Erythematosus-SLE-at-ACR-Convergence-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4077","ACR","BK4110","SLE","BK4007"],"gpt_icon":0}],"pageSize":16,"totalPage":9,"pageCount":5,"totalSize":129}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-28","symbol":"SLE","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2024-11-14","symbol":"SLE","fiscalQuarterEnding":"2024/09","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.54},{"market":"US","date":"2024-08-14","symbol":"SLE","fiscalQuarterEnding":"2024/06","expectedEps":-0.62,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.6},{"market":"US","date":"2024-05-15","symbol":"SLE","fiscalQuarterEnding":"2024/03","expectedEps":-1.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":1},{"market":"US","date":"2024-03-27","symbol":"SLE","fiscalQuarterEnding":"2023/12","expectedEps":-1.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711512000000,"reportTimeType":"post","actualEps":-3.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1694059200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2025-03-28","current":-0.230354,"percent":0.696133,"low":-0.555206,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"high":-0.044016,"avg":-0.276106,"sd":0.108282,"marketCap":5671557},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557}],"updateTime":1743451357866}}}